Russia's RDIF rejects Brazilian regulator Anvisa's comments about Sputnik V as 'incorrect'

The Russian Direct Investment Fund (RDIF) on Tuesday said comments about the Sputnik V COVID-19 vaccine from Brazilian health regulator Anvisa were incorrect and that a decision to delay the vaccine's approval could be politically motivated.

Anvisa on Monday rejected importing the Russian-made vaccine requested by state governors battling a deadly second wave of the virus that is battering Latin America's largest nation, saying technical staff had highlighted "inherent risks" and "serious" defects.